A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Ono Pharmaceutical Co., Ltd..
Phase
—
Status
Completed
Study type
Observational
Enrollment
500actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-29 | actual | When the study began enrolling |
| Primary completion | 2026-01-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-16 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stomach Neoplasms
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Up to approximately 4 years
Objective response rate (ORR)
measured Up to approximately 4 years
Incidence of all immune-related adverse events (irAE) according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0
measured Up to approximately 4 years
Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation
measured Up to approximately 4 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed